REMS 2.0: FDA Refining New Drug Safety Tools
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision – but use of Risk Evaluation and Mitigation Strategies is actually declining. As FDAAA turns three, it is clear that REMS are going through some growing pains. The new tools will be refined, but they are definitely here to stay.
You may also be interested in...
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Congress is not expected to pile as many new responsibilities on FDA in the upcoming Prescription Drug User Fee Act reauthorization as in 2007’s FDA Amendments Act.
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements
Although often overshadowed by the novelty of FDA’s sweeping authority in constructing Risk Evaluation and Mitigation Strategies, examination of agency review documents suggest that the FDA Amendments Act’s other safety innovation, granting FDA the ability to require (i.e., enforce) post-marketing studies, is increasingly important to the approval of NDAs with marginal data on issues of concern.